SCHEMBL10077369

SCHEMBL10077369

O=Cc1cc(C(=O)CN(CCCCCCOCCCCc2ccccc2)Cc2ccccc2)ccc1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK1 P06493 1/20 0.42
▸ MAOB P27338 4/20 0.40
▸ BCHE P06276 3/20 0.37
▸ ACHE P22303 3/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ADRB2 P07550 1/20 0.37
▸ ADRB1 P08588 1/20 0.37
▸ HTR1A P08908 1/20 0.37
▸ CHRM5 P08912 1/20 0.37
▸ ADRB3 P13945 1/20 0.37
▸ DRD2 P14416 1/20 0.37
▸ ADRA2B P18089 1/20 0.37
▸ DRD4 P21917 1/20 0.37
▸ SLC6A2 P23975 1/20 0.37
▸ FPR3 P25089 1/20 0.37
▸ ADRA1D P25100 1/20 0.37
▸ HTR1D P28221 1/20 0.37
▸ HTR1B P28222 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ HTR2C P28335 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27926712 0.94 CDK1 (0.47) CDK1ACHE
SCHEMBL14030634 0.87 CDK1 (0.43) CDK1
SCHEMBL10477860 0.85 KDM4E (0.41) MAOBBCHEACHEKDM4EADRB2
SCHEMBL10076826 0.83 MAOB (0.43) MAOBMEN1KMT2A
SCHEMBL10592068 0.83 MAOB (0.40) MAOBBCHEACHEKDM4EADRB2
SCHEMBL6292406 0.83 L3MBTL1 (0.44) CDK1KDM4EADRB2ADRB1HTR1A
SCHEMBL9574173 0.81 MAOB (0.43) MAOBBCHEACHEMEN1KMT2A
SCHEMBL19422883 0.80 MAOB (0.35) MAOBBCHEACHE
SCHEMBL19422886 0.80 ADRB2 (0.48) CDK1KDM4EADRB2ADRB1HTR1A
SCHEMBL10477749 0.78 ADRB2 (0.46) CDK1MAOBKDM4EADRB2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103420856-B Salmeterol preparation method ASYMCHEM LAB TIANJIN CO LTD 2015-07-01 — — CN claimed
WO-2017168431-A1 PROCESS FOR THE PREPARATION OF SALMETEROL XINAFOATE DAVULURI RAMAMOHAN RAO (IN) 2017-10-05 — — WO disclosed
US-8648214-B2 Processes suitable for the preparation of salmeterol GENERICS [UK] LIMITED (GB) 2014-02-11 — — US disclosed
US-8648214-B2 Processes suitable for the preparation of salmeterol GENERICS [UK] LIMITED (GB) 2014-02-11 — — US disclosed
WO-2012032546-A2 PROCESS FOR THE PREPARATION OF SALMETEROL AND ITS INTERMEDIATES CADILA HEALTHCARE LIMITED (IN) 2012-03-15 — — WO disclosed
US-20080262267-A1 NOVEL PROCESS GENERICS [UK] LIMITED (GB) 2008-10-23 — — US disclosed
US-20080262267-A1 NOVEL PROCESS GENERICS [UK] LIMITED (GB) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262267-A1 NOVEL PROCESS CYP4A11, HSD3B1, HSD11B1 CDK1 2767/4885MAOB 278/4885BCHE 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback